Key additions deepen drug development expertise and position the Company to advance pipeline VANCOUVER, British Columbia, Feb. 10, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders…

Source

Previous articleMind Cure Announces Closing of $23 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option
Next articleSilo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds